(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Sev­er­al FDA ex­perts who gath­ered Thurs­day to con­sid­er the land­mark ap­proval of Vas­cepa to re­duce car­dio events in an at-risk pop­u­la­tion voiced their un­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.